Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

204 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-13

Study Completion Date

2020-12-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is associated with an increased risk of cardiovascular complications, as a reflection of the chronic inflammatory status. Monocytes-macrophages in diabetic subjects present impaired arachidonic acid metabolism. Moreover, atheromatous plaques in diabetic subjects seem to be significantly enriched in 2-AA-LPC (2-arachidonoyl-lysophosphatidylcholine) and are more inflammatory and more likely to rupture than are plaques in non-diabetic subjects. We therefore hypothesize that this vulnerability of atheromatous plaques in diabetic subjects could be explained by impaired 2-AA-LPC metabolism within the plaque.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Types of Intracellular Bacteria in Atherosclerotic Plaques and Analysis of Risk Factors

NCT06935279

Carotid Artery Stenosis Carotid Artery Stenosis Asymptomatic Carotid Artery Stenosis Symptomatic +6 more

RECRUITING

Molecular Mechanisms and Carotid Atherosclerosis

NCT03962686

Diabetes Mellitus, Type 2 Atherosclerosis of Artery Atherosclerotic Plaque

COMPLETED

Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.

NCT05708547

Coronary Atherosclerosis

COMPLETED

Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis

NCT02124928

Atherosclerosis Carotid Artery Disease

UNKNOWN

PIoglitazone for PrEvention of Restenosis in Diabetic Patients

NCT00376870

Coronary Atherosclerosis Coronary Restenosis Diabetes

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetics

blood samples

Intervention Type PROCEDURE

3 tubes (5 ml volume) collected during surgery

recover samples of atheromatous plaque

Intervention Type PROCEDURE

a carotid sample collected during surgery

Non-diabetics

blood samples

Intervention Type PROCEDURE

3 tubes (5 ml volume) collected during surgery

recover samples of atheromatous plaque

Intervention Type PROCEDURE

a carotid sample collected during surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples

3 tubes (5 ml volume) collected during surgery

Intervention Type PROCEDURE

recover samples of atheromatous plaque

a carotid sample collected during surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have provided explicit consent
* Patients older than 18 years
* Patients about to undergo surgery for carotid stenosis
* Haemoglobin ≥ 7g/dl at the time the sample is taken
* Respect the maximum volume of blood taken (treatment + research) in 30 days

SPECIFIC TO DIABETICS

\- Patients with type 1 or 2 diabetes diagnosed more than 6 months earlier